Thompson Siegel & Walmsley LLC acquired a new stake in shares of Eton Pharmaceuticals, Inc. (NASDAQ:ETON – Free Report) during the 2nd quarter, Holdings Channel reports. The fund acquired 127,724 shares of the company’s stock, valued at approximately $420,000.
A number of other hedge funds have also recently bought and sold shares of ETON. Victory Capital Management Inc. acquired a new position in Eton Pharmaceuticals in the 4th quarter valued at $123,000. Acadian Asset Management LLC increased its stake in Eton Pharmaceuticals by 13.7% in the first quarter. Acadian Asset Management LLC now owns 156,386 shares of the company’s stock valued at $585,000 after purchasing an additional 18,898 shares during the last quarter. Westside Investment Management Inc. boosted its stake in Eton Pharmaceuticals by 2.0% in the 2nd quarter. Westside Investment Management Inc. now owns 585,400 shares of the company’s stock worth $1,926,000 after buying an additional 11,440 shares during the last quarter. Finally, Opaleye Management Inc. boosted its stake in Eton Pharmaceuticals by 4.1% in the 4th quarter. Opaleye Management Inc. now owns 2,529,887 shares of the company’s stock worth $11,081,000 after buying an additional 99,617 shares during the last quarter. Institutional investors and hedge funds own 27.86% of the company’s stock.
Eton Pharmaceuticals Stock Up 6.8 %
Shares of ETON opened at $5.50 on Tuesday. The firm has a market cap of $141.30 million, a PE ratio of 137.50 and a beta of 1.30. The company’s fifty day moving average is $4.02 and its two-hundred day moving average is $3.76. Eton Pharmaceuticals, Inc. has a fifty-two week low of $3.03 and a fifty-two week high of $5.64.
Insider Buying and Selling
In other Eton Pharmaceuticals news, major shareholder Opaleye Management Inc. acquired 57,500 shares of the firm’s stock in a transaction on Tuesday, September 10th. The stock was bought at an average cost of $4.65 per share, for a total transaction of $267,375.00. Following the completion of the purchase, the insider now directly owns 2,660,000 shares in the company, valued at $12,369,000. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 14.89% of the company’s stock.
Wall Street Analyst Weigh In
Separately, HC Wainwright reiterated a “buy” rating and set a $9.00 price objective on shares of Eton Pharmaceuticals in a report on Wednesday, September 4th.
Check Out Our Latest Stock Analysis on ETON
Eton Pharmaceuticals Company Profile
Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.
Read More
- Five stocks we like better than Eton Pharmaceuticals
- Best ESG Stocks: 11 Best Stocks for ESG Investing
- Palo Alto Analysts Drive it to New Highs: 50% Upside Is Possible
- What is the S&P/TSX Index?
- Roblox’s Growth Beyond Kids: Stock Set for Major Moves
- 3 Must-Buy Warren Buffett Stocks for Volatile Times
- 5 Oversold Stocks to Buy Right Now
Want to see what other hedge funds are holding ETON? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eton Pharmaceuticals, Inc. (NASDAQ:ETON – Free Report).
Receive News & Ratings for Eton Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eton Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.